Amperos Health, a startup that uses AI agents to help healthcare providers recover unpaid insurance claims, has closed a $16 million Series A funding round. The announcement also marks the launch of what the company calls the industry’s first AI-native denial management and revenue recovery platform. Michal Miernowski, co-founder and CEO, leads the company.
The financial pressure on US healthcare providers has been building for years. Payers initially denied 11.8% of claims in 2024, up from 11.5% in 2023 and a 15.7% increase from 2020, according to Healthcare Finance News. The press release puts the revenue impact at $262 billion in annual losses for providers, who then spend more than $26 billion each year trying to recover what they are owed. A separate survey by AAPC found that 84% of organizations now list reducing denials as a top priority, while 77% remain concerned that payers will not ultimately pay what they owe.
Bessemer Venture Partners led the round, with Uncork Capital and Neo also participating.
Rising Denial Rates and a Workforce That Can’t Keep Up
Revenue cycle management, known in the industry as RCM, is how hospitals and medical practices track and collect payment for the services they provide. When an insurer denies a claim, the provider must follow up through payer portals, fix paperwork, resubmit the claim, and sometimes go through several rounds of appeals before seeing a single dollar. It is time-consuming work, and it requires people who know exactly what they are doing.
The staffing situation makes this harder. According to the press release, 63% of RCM teams are currently understaffed, and administrative roles turn over at a rate of 32% per year. Many denied claims go uncontested simply because there is not enough staff to chase them. Research cited by TechTarget confirms that denial management demands a high level of expertise, yet qualified workers are consistently hard to find across the sector.
“Denials are one of healthcare’s fastest-growing pain points: a growing portion of claims denied, hundreds of billions in lost revenue, and RCM teams that are chronically understaffed. It’s a broken process ripe for AI transformation.” — Sofia Guerra, Partner, Bessemer Venture Partners.
How Amperos Plans to Use the $16M
The new capital will fund expansion of the company’s provider base and improvements to its analytics tools. Those tools are designed to give providers clearer insight into what is causing their denials and where they can make changes earlier in the billing process to avoid them. Amperos has also said it plans to extend its AI capabilities into other parts of the RCM workflow.
“Complexity in healthcare revenue cycle management (RCM) should not be the norm, and that’s why our mission at Amperos is to streamline the denial and collections process so providers can focus on what matters most – operating their practices and serving their patients,” said Michal Miernowski, CEO and Co-Founder of Amperos Health. “I’m thrilled to announce our most recent funding round, which will be critical as Amperos accelerates its growth to serve more providers, expands its analytics capabilities and launches new agentic capabilities in other RCM workflows.” — Michal Miernowski, CEO and Co-Founder, Amperos Health.
The longer-term direction goes beyond recovering denied claims. Amperos wants to help providers stop denials from happening in the first place, building tools that address problems earlier in the process rather than cleaning them up afterward.
What Amperos Does and How It Differs from Other RCM Tools
The platform handles the full insurance collections process. That means portal follow-ups, phone calls to insurers, corrected claim submissions, medical record uploads, and formal appeals. It uses large language models, a type of AI technology that can read, write, and communicate across different formats, to carry out these tasks from beginning to end. For claims that require specialist knowledge or judgment, a team of experienced RCM professionals works alongside the AI.
Most RCM software automates only one piece of this. A tool might write appeal letters, or navigate payer portals, but providers still need people or other systems to handle the rest. Amperos processes the full sequence without passing work between separate tools or teams. That end-to-end approach is the core of what the company is selling, and it is the detail Bessemer specifically highlighted when explaining its decision to invest.
Customer results reported in the press release offer some early evidence. DOCS Dermatology recovered 24% more claims without hiring additional staff. Across the full provider base, Amperos has processed over 500,000 claims at more than 3,000 clinical locations across all 50 states, recovering nearly $700 million in revenue per year.
The Investors Behind the Round
This Series A follows a $4.2 million seed round announced in June 2025, bringing total funding raised to $20.2 million.
Bessemer Venture Partners led the current round, with Uncork Capital and Neo participating. Partner Sofia Guerra represented Bessemer and pointed to the end-to-end automation of the denial workflow as the key differentiator. In her view, most platforms available today leave gaps somewhere in the process. Amperos, she argued, does not.
